Association between polymorphism of a gene dopamine-β-hydroxylases and the level of adipokines of blood at patients with the first episode of schizophrenia at antipsychotic therapy
Suggested citation:
Ozornin AS, Govorin NV, Sakharov AV, et al. [Association between polymorphism of a gene dopamine-β-hydroxylases and the level of adipokines of blood at patients with the first episode of schizophrenia at antipsychotic therapy]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(3):67-75. Russian
In a longitudinal prospective experimental study aiming to study the association between the genetic polymorphism of dopamine-β-hydroxylase rs1611115 (C-1021T) and the serum levels of adiponectin, adipsin, and leptin in patients with the first episode of schizophrenia treated with haloperidol and risperidone, 212 patients with the first episode of paranoid schizophrenia (F20.09) were examined. The content of leptin in the blood serum of the C/T+T/T genotypes was significantly higher compared to that of the carriers of the C/C genotype. During haloperidol therapy, the content of adiponectin increased in carriers of the C/C genotype, and the concentration of leptin decreased in carriers of the C/T+T/T genotypes. When using risperidone in carriers of the C/C genotype, an increase in the value of leptin was observed.
Keywords schizophrenia; antipsychotics; adiponectin; adipsin; leptin; dopamine-β-hydroxylase gene polymorphism
1. Naderyan Fe'li S, Yassini Ardekani SM, Fallahzadeh H, et al. Dehghani A. Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics. Med. J. Islam. Repub. Iran. 2019;33:97. DOI: https://doi.org/10.34171/mjiri.33.97; PMID: 31696091; PMCID: PMC6825382 2. Shojaeimotlagh V, Hashiehbaf A, Karami M, et al. Prevalence of metabolic syndrome in Iranian patients with schizophrenia: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(1):143–7. DOI: https://doi.org/10.1016/j.dsx.2018.08.014; PMID: 30641687 3. Mazo GE, Kibitov AO. [Genetic Markers of Metabolic Side-Effects Risks in Second-Generation Antipsychotic Therapy]. Sovremennaya terapiya psikhicheskikh rasstroistv [Contemporary therapy of mental disorders]. 2017;(4):2–10. (In Russ.) DOI: https://doi.org/10.21265/PSYPH.2017.43.8415 4. Gassó P, Arnaiz JA, Mas S, Lafuente A, et al. Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. J Psychopharmacol. 2020; 34(5):514–23. DOI: https://doi.org/10.1177/0269881120903462; PMID: 32009515 5. Gonzalez-Lopez E, Vrana KE. Dopamine beta-hydroxylase and its genetic variants in human health and disease. J Neurochem. 2020;152(2):157–81. DOI: https://doi.org/10.1111/jnc.14893; PMID: 31613389 6. Zhou N, Yu Q, Li X, et al. Association of the dopamine β-hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia. Hum Psychopharmacol. 2013;28(3):230–7. DOI: https://doi.org/10.1002/hup.2311; PMID: 23559427 7. Punchaichira TJ, Mukhopadhyay A, Kukshal P, et al. Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects. J Psychopharmacol. 2020;34(3):358–69. DOI: https://doi.org/10.1177/0269881119895539; PMID: 31913053; PMCID: PMC7150076 8. Ozornin AS, Govorin NV, Sakharov AV. [The Role of Adipokines in the Development of Metabolic Disorders in Schizophrenic Patients]. Doktor.Ru. [Doctor.Ru]. 2020;19(4):50–4. (In Russ.) DOI: https://doi.org/10.31550/1727-2378-2020-19-4-50-54 9. Vasilenko MA, Kirienkova EV, Skuratovskaya DA, et al. Rol' produktsii adipsina i leptina v formirovanii insulinorezistentnosti u bol'nykh abdominal'nym ozhireniem. Doklady akademii nauk. 2017;475(3):336–41. (In Russ.) 10. D'souza AM, Neumann UH, Glavas MM, et al. The glucoregulatory actions of leptin. Mol Metab. 2017 May 4;6(9):1052–65. DOI: https://doi.org/10.1016/j.molmet.2017.04.011; PMID: 28951828; PMCID: PMC5605734 11. Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409–17. Epub 2019 Jun 8. DOI: https://doi.org/10.1016/j.dsx.2019.06.005; PMID: 31405652 12. Gomes A, Leite F, Ribeiro L. Adipocytes and macrophages secretomes coregulate catecholamine-synthesizing enzymes. Int J Med Sci. 2021;18(3):582–92. DOI: https://doi.org/10.7150/ijms.52219; PMID: 33437193; PMCID: PMC7797554 13. Sun F, Lei Y, You J, et al. Adiponectin modulates ventral tegmental area dopamine neuron activity and anxiety-related behavior through AdipoR1. Mol Psychiatry. 2019;24(1):126–44. Epub 2018 Jul 9. DOI: https://doi.org/10.1038/s41380-018-0102-9; PMID: 29988086; PMCID: PMC6325675 14. Bartoli F, Lax A, Crocamo C, et al. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;56:179–89. Epub 2015 Mar 14. DOI: https://doi.org/10.1016/j.psyneuen.2015.03.012; PMID: 25827962 15. Song X, Fan X, Song X, et al. Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr Res. 2013;150(1):269–73. Epub 2013 Aug 19. DOI: https://doi.org/10.1016/j.schres.2013.07.044; PMID: 23968860 16. Malashenkova IK, Krynskii SA, Ogurtsov DP, et al. [A role of the immune system in the pathogenesis of schizophrenia]. Zh Nevrol Psikhiatr Im SS Korsakova. 2018;118(12):72–80. (In Russ.) DOI: https://doi.org/10.17116/jnevro201811812172; PMID: 30698566 17. Zhou Q, Ge Q, Ding Y, et al. Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Investig. 2018;9(5):1128–34. Epub 2018 Mar 22. DOI: https://doi.org/10.1111/jdi.12819; PMID: 29432659; PMCID: PMC6123022 18. Bocchio-Chiavetto L, Zanardini R, Tosato S, et al. Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain Behav Immun. 2018;70:315–24. DOI: https://doi.org/10.1016/j.bbi.2018.03.013; PMID: 29548996 19. Martorell L, Muntané G, Porta-López S, et al. Increased levels of serum leptin in the early stages of psychosis. J Psychiatr Res. 2019;111:24–9. Epub 2019 Jan 11. DOI: https://doi.org/10.1016/j.jpsychires.2019.01.006; PMID: 30660810 20. Veru-Lesmes F., Guay S., Shah J.L. et al. Adipose tissue dysregulation at the onset of psychosis: Adipokines and social determinants of health. Psychoneuroendocrinology. 2021;123:104915. Epub 2020 Oct 15. DOI: https://doi.org/10.1016/j.psyneuen.2020.104915; PMID: 33130407 21. Gorobets LN, Bulanov VS, Vasilenko LM, et al. [Metabolic disorders in patients with schizophrenia treated with atypical antipsychotic drugs] Zh Nevrol Psikhiatr Im SS Korsakova. 2012;112(9):90–6. (In Russ.) PMID: 23373080 22. Bhaduri N, Mukhopadhyay K. Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cell Mol Neurobiol. 2008;28(3):343–50. Epub 2008 Jan 3. DOI: https://doi.org/10.1007/s10571-007-9256-8; PMID: 18172755 23. Tay YH, Lee J. The relationship between serum adiponectin levels, cardiometabolic indices and metabolic syndrome in schizophrenia. Asian J Psychiatr. 2019;43:1–6. Epub 2019 Apr 27. DOI: https://doi.org/10.1016/j.ajp.2019.04.006; PMID: 31059867 24. Balõtšev R, Haring L, Koido K, et al. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Interv Psychiatry. 2019;13(1):101–9. Epub 2017 Jul 18. DOI: https://doi.org/10.1111/eip.12457; PMID: 28719155 25. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011;25(12):1035–59. DOI: https://doi.org/10.2165/11596300-000000000-00000; PMID: 22133326
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10307
Article Metrics
Metrics powered by PLOS ALM